John Gildea Net Worth

The estimated Net Worth of John Gildea is at least $796 Tausend dollars as of 6 February 2017. John Gildea owns over 15,000 units of Misonix Inc stock worth over $796,200 and over the last 20 years John sold MSON stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

John Gildea MSON stock SEC Form 4 insiders trading

John has made over 2 trades of the Misonix Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently John exercised 15,000 units of MSON stock worth $81,300 on 6 February 2017.

The largest trade John's ever made was exercising 15,000 units of Misonix Inc stock on 6 February 2017 worth over $81,300. On average, John trades about 2,500 units every 60 days since 2005. As of 6 February 2017 John still owns at least 30,000 units of Misonix Inc stock.

You can see the complete history of John Gildea stock trades at the bottom of the page.

What's John Gildea's mailing address?

John's mailing address filed with the SEC is C/O GILDEA MANAGEMENT COMPANY, 65 VITTI STREET, NEW CANAAN, CT, 06840.

Insiders trading at Misonix Inc

Over the last 21 years, insiders at Misonix Inc have traded over $4,371,211 worth of Misonix Inc stock and bought 1,536,334 units worth $6,620,934 . The most active insiders traders include Stavros G. Vizirgianakis, Gary Gelman und Michael A Jr Mcmanus. On average, Misonix Inc executives and independent directors trade stock every 29 days with the average trade being worth of $378,885. The most recent stock trade was executed by Sharon W Klugewicz on 20 May 2020, trading 825 units of MSON stock currently worth $10,032.

What does Misonix Inc do?

Misonix, Inc. is a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative tissue products. Its surgical team markets and sells BoneScalpel and SonaStar, which facilitate precise bone sculpting and removal of soft and hard tumors and tissue, primarily in the areas of neurosurgery, orthopedic, plastic and maxillo-facial surgery. The Company's wound team markets and sells TheraSkin, Therion, TheraGenesis and SonicOne to debride, treat and heal chronic and traumatic wounds in inpatient, outpatient and physician office sites of service. At Misonix, Better Matters! That is why throughout the Company's history, Misonix has maintained its commitment to medical technology innovation and the development of products that radically improve outcomes for patients.

Complete history of John Gildea stock trades at Misonix Inc

Misonix Inc executives and stock owners

Misonix Inc executives and other stock owners filed with the SEC include:

• Stavros Vizirgianakis,
  President, Chief Executive Officer, Director
• Charles Miner,
  Independent Director
• Paul LaViolette,
  Independent Chairman of the Board
• T Guy Minetti,
  Director
• Patrick A Mc Brayer,
  Director
• John Gildea,
  Director
• Thomas M Patton,
  Director
• Michael L Consilvio,
  VP - Marketing
• Richard A Zaremba,
  Vice President and CFO
• John Joseph Salerno,
  VP, Quality & Regulatory
• Howard Alliger,
  Director
• Daniel Voic,
  VP-R&D and Engineering
• Joseph J Brennan,
  Vice President, Operations
• Gary Gelman,
  10% owner
• Michael A Jr Mcmanus,
  President, CEO
• Michael Koby,
  Director
• Christopher H Wright,
  Vice President - U.S. Sales
• Capital Management, Llc1315...,
  
• Gwendolyn A Watanabe,
  Director
• Jonathan Jay Waggoner,
  SVP, Wound Sales
• Thomas F Oneill,
  Director
• Frank Napoli,
  VP, Operations
• Michael C Ryan,
  SVP, Medical Division
• W Paul Constantine,
  SVP, Strat. Plan. & New Prod.
• Kenneth Coviello,
  V.P - Medical Devices
• Ronald Manna,
  VP-New Prod. Dev. & Reg. Aff.
• Bernhard Berger,
  VP-Industrial/Scientific Prod.
• Allan Richard Staley,
  President
• Linwood A. Staub,
  Sr. VP Wound
• Robert S Ludecker,
  SVP, Global Sales - Marketing
• Joseph P Dwyer,
  Chief Financial Officer
• Pat Beyer,
  Director
• Sharon W Klugewicz,
  Chief Operating Officer